Publications

Molekulare Medizin - AG Biniossek, Massenspektrometrie - Peptidanalytik und Proteinanalytik (Proteomics) - Publikationen

2020	Uhl FM, Chen S, O'Sullivan D, Edwards-Hicks J, Richter G, Haring E, Andrieux G, Halbach S, Apostolova P, Buscher J, Duquesne S, Melchinger W, Sauer B, Shoumariyeh K, Schmitt-Graeff A, Kreutz M, Lubbert M, Duyster J, Brummer T, Boerries M, Madl T, Blazar BR, Gross O, Pearce EL, Zeiser R Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med 2020 Oct 28 12doi: 10.1126/scitranslmed.abb8969 Pubmed/33115954
2019	Kohler M, Ehrenfeld S, Halbach S, Lauinger M, Burk U, Reischmann N, Cheng S, Spohr C, Uhl FM, Kohler N, Ringwald K, Braun S, Peters C, Zeiser R, Reinheckel T, Brummer T B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene 2019 Feb 38:1324-1339 doi: 10.1038/s41388-018-0663-8 https://www.ncbi.nlm.nih.gov/pubmed/30659267 Sies K, Spohr C, Grunder A, Todorova R, Uhl FM, Huber J, Zeiser R, Pahl HL, Becker H, Aumann K, Brummer T, Halbach S Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia. Hemasphere 2019 Apr 3:e184 doi: 10.1097/HS9.0000000000000184, Pubmed/31723823
2018	Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene 2018 Mar 37:1576-1593 doi: 10.1038/s41388-017-0063-5 https://www.ncbi.nlm.nih.gov/pubmed/29326440 Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Muller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lubbert M, Rummelt C, Bertz H, Wasch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rosler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stolzel F, Ordemann R, Muller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kroger N, Ayuk F, Vago L, Ciceri F, Muller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dorfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Borries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socie G, Caligiuri MA, Ruggiero E, Bonini C, Hacker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018 Mar 24:282-291 doi: 10.1038/nm.4484 Pubmed/29431743
	Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholoma M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kroger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 2018 Feb 21 10doi: 10.1126/scitranslmed.aam7729, Pubmed/29467301
2017	Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Kohler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. EBioMedicine 2017 Jun 20:79-97 doi: 10.1016/j.ebiom.2017.04.015, Pubmed/28499923
2016	Bier D, Bartel M, Sies K, Halbach S, Higuchi Y, Haranosono Y, Brummer T, Kato N, Ottmann C Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface. ChemMedChem 2016 Apr 19 11:911-8 doi: 10.1002/cmdc.201500484, Pubmed/26644359
	Halbach S, Dengjel J, Brummer T Quantitative Proteomics Analysis of Leukemia Cells. Methods Mol Biol 2016 1465:139-48 doi: 10.1007/978-1-4939-4011-0_12, Pubmed/27581145
	Halbach S, Hu Z, Gretzmeier C, Ellermann J, Wohrle FU, Dengjel J, Brummer T Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell Commun Signal 2016 Feb 24 14:6 doi: 10.1186/s12964-016-0129-y, Pubmed/26912052
	Halbach S, Kohler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K, Brummer T Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. Leukemia 2016 Sep 30:1942-5 doi: 10.1038/leu.2016.92, Pubmed/27125306
	International Cancer Genome Consortium PedBrain Tumor P Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 2016 Nov 22:1314-1320 doi: 10.1038/nm.4204, Pubmed/27748748
2015	Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A, Kohler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Lassmann S, Wasch R, Zeiser R Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. Int J Cancer 2015 May 15 136:2328-40 doi: 10.1002/ijc.29289 Pubmed/25346496
	Herr R, Kohler M, Andrlova H, Weinberg F, Moller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res 2015 Jan 1 75:216-29 doi: 10.1158/0008-5472.CAN-13-3686, Pubmed/25381152
	Willmann L, Erbes T, Halbach S, Brummer T, Jager M, Hirschfeld M, Fehm T, Neubauer H, Stickeler E, Kammerer B Exometabolom analysis of breast cancer cell lines: Metabolic signature. Scientific reports 2015 Aug 21 5:13374 doi: 10.1038/srep13374, Pubmed/26293811
	Willmann L, Schlimpert M, Halbach S, Erbes T, Stickeler E, Kammerer B Metabolic profiling of breast cancer: Differences in central metabolism between subtypes of breast cancer cell lines. Journal of chromatography B, Analytical technologies in the biomedical and life sciences 2015 Sep 1 1000:95-104 doi: 10.1016/j.jchromb.2015.07.021 Pubmed/26218769
2013	Halbach S, Rigbolt KT, Wohrle FU, Diedrich B, Gretzmeier C, Brummer T, Dengjel J Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. Cell Commun Signal 2013 Apr 22 11:30 doi: 10.1186/1478-811X-11-30 Pubmed/23607741
	Wohrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Lassmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 2013 Jan 27:118-29 doi: 10.1038/leu.2012.222 Pubmed/22858987
2012	Roring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012 May 30 31:2629-47 doi: 10.1038/emboj.2012.100, Pubmed/22510884
	Wohrle FU, Halbach S, Brummer T The versatile role of Gab1 in the circulatory system. Circ J 2012 76:1838-9 doi: 10.1253/circj.cj-12-Pubmed/22785000

Publications

Start Footer

Personal tools

Document Actions

Publications

Start Footer

Personal tools